Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will assess the additional costs to the NHS if Israeli-owned or Israeli-based companies were banned from supplying generic medicines to the NHS.

We do not routinely collect information on where pharmaceutical manufacturers are based, or whether they have connections with particular countries. Any company with the necessary regulatory authorisations can supply medicines to the National Health Service. However, some 100 million prescription items for medicines used in the community in England are estimated to come from companies based in Israel. This includes some medicines where one of these companies will be the main supplier. Banning these supplies would most likely cause significant shortages of some medicines important for patient health and have a significant impact on competition and in all likelihood increase prices paid by the NHS.